- Home
- PLX vs RCMT Comparison
PLX vs RCMT Comparison
Compare PLX & RCMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- RCMT
- Stock Information
- Founded
- PLX 1993
- RCMT 1971
- Country
- PLX United States
- RCMT United States
- Employees
- PLX N/A
- RCMT N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- RCMT Professional Services
- Sector
- PLX Health Care
- RCMT Consumer Discretionary
- Exchange
- PLX Nasdaq
- RCMT Nasdaq
- Market Cap
- PLX 204.9M
- RCMT 200.2M
- IPO Year
- PLX 1998
- RCMT N/A
- Fundamental
- Price
- PLX $1.85
- RCMT $22.42
- Analyst Decision
- PLX Strong Buy
- RCMT Strong Buy
- Analyst Count
- PLX 1
- RCMT 2
- Target Price
- PLX $15.00
- RCMT $33.50
- AVG Volume (30 Days)
- PLX 1.1M
- RCMT 34.0K
- Earning Date
- PLX 11-13-2025
- RCMT 11-06-2025
- Dividend Yield
- PLX N/A
- RCMT N/A
- EPS Growth
- PLX N/A
- RCMT N/A
- EPS
- PLX 0.08
- RCMT 1.76
- Revenue
- PLX $61,948,000.00
- RCMT $299,916,000.00
- Revenue This Year
- PLX $14.53
- RCMT $15.03
- Revenue Next Year
- PLX $75.77
- RCMT $7.49
- P/E Ratio
- PLX $24.02
- RCMT $12.72
- Revenue Growth
- PLX 62.79
- RCMT 11.01
- 52 Week Low
- PLX $1.01
- RCMT $13.18
- 52 Week High
- PLX $3.10
- RCMT $28.27
- Technical
- Relative Strength Index (RSI)
- PLX 38.39
- RCMT 30.02
- Support Level
- PLX $2.31
- RCMT $22.64
- Resistance Level
- PLX $2.55
- RCMT $24.56
- Average True Range (ATR)
- PLX 0.15
- RCMT 0.86
- MACD
- PLX -0.06
- RCMT -0.26
- Stochastic Oscillator
- PLX 23.70
- RCMT 7.89
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.